12,458 research outputs found
Oncologie Médicale
No full textBoth in 1995 and 1996 we will have seen and will see the introduction of new cytotoxic and other agents to treat the most common cancers like lung, colon and breast. Taxoids, antimetabolites, topoisomerase I inhibitors have new mechanisms of action and seem to provide hitherto unexpected therapeutic gains. Only a wider experience will tell the exact role these agents have to play, and will show if their price is indeed justified by an advantage ta the patient, as it would seem at a first glance
Nutrition education in medical schools (NEMS) project: Promoting clinical nutrition in medical schools – Perspectives from different actors
No full textBackground & aims: Nutrition education is not adequately represented in the medical curriculum, and this prompted the European Society for Clinical Nutrition and Metabolism (ESPEN) to launch the Nutrition Education in Medical Schools (NEMS) Project in 2017. The aim of this original paper was to describe the perspectives of different actors in the promotion of nutrition education in medical schools. Methods: On 11 November 2021, an online meeting was held on this topic, where nine representatives from different backgrounds participated in the scientific programme. More than 640 participants registered to this webinar. Results: The different models of Nutrition Education in Medical Schools were introduced by Prof. Cristina Cuerda (Spain) and Prof. Maurizio Muscaritoli (Italy). The students' perspective was given by Ms. Alexandra Archodoulakis (Germany) and Ms. Sila Gürbüz (Turkey), representing the European Medical Students' Association. The dietitian's perspective was given by Dr. Kirsten Berk (The Netherlands), whereas Dr. Matti Aapro (Switzerland) gave the medical doctor (oncology)'s perspective. Ms. Clare Farrand (Australia) gave the WHO perspective and Dr. Kristiina Patja (Finland) explained the healthy lifestyle teaching to medical students. Lastly, Prof. Michael Chourdakis (Greece) and Prof. Zeljko Krznaric (Croatia) hosted the round-table discussion. Conclusions: There was strong agreement among the representatives from different settings joining this ESPEN initiative that increasing nutritional knowledge and skills of young doctors is now possible and will launch a virtuous cycle that will proactively involve all the other healthcare professionals working in the nutritional field
Oral vinorelbine: role in the management of metastatic breast cancer.
No full textThe treatment of advanced breast cancer is continually evolving, with the aim of improving the quality and duration of remission and, in some instances, survival. In this setting, the importance of quality of life cannot be underestimated, and growing attention is being paid to treatment convenience and compliance. New anticancer agents have improved efficacy, but for many of them, toxicity often remains a problem. Vinorelbine seems to represent both an active and a well tolerated treatment for metastatic breast cancer. In particular, the oral formulation has similar efficacy to that of the injectable formulation and has demonstrated generally favourable tolerability, with a high degree of acceptance by both patients and physicians. The availability of this and other novel, well tolerated and effective treatments provides greater potential to tailor treatment to meet individual patient needs and, therefore, also provide the potential to improve patient outcomes. Preliminary data suggest that oral vinorelbine may permit continued, effective chemotherapy when further parenteral therapy with more intensive and more toxic agents is considered inappropriate. Early findings also suggest that oral vinorelbine, when administered together with another new oral agent, capecitabine, may be a valid choice in metastatic breast cancer treatment. Furthermore, vinorelbine plus the monoclonal antibody trastuzumab, with or without oral capecitabine, appears to be another regimen that may be worthy of additional study in patients with human epidermal growth factor-2 positive advanced breast cancer
Ms. Courtney Chartier, RWWL AUC, August 2011
No full textThis video is a conversation with Ms. Courtney Chartier. Ms. Chartier talks about her work on the "New Georgia Encyclopedia" and "Online Voter Education Project." Andrea Jackson, AUC Woodruff Library, is the interviewer
Ms. Neely Terrell, RWWL AUC, March 2012
No full textThis video is a conversation with Ms. Neely Terrell. Ms. Terrell talks about her book, "Super Singles Activate". Anthony Kinsey and Jahnesta Horney, AUC Woodruff Library, are the interviewers
Ms. Felesha Love, Spelman College, January 2016
No full textThis video is a conversation with Felesha Love. Ms. Love talks about her book, "Brave Leap to Freedom: Integrating Mind, Body, and Spirit to Cultivate Healthy Relationships". Jordan Moore, AUC Woodruff Library, is the interviewer
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
No full textBone mineral density (BMD)-based guidelines for bone-directed therapy in women with early breast cancer (EBC) appear inadequate for averting fractures, particularly during aromatase inhibitor (AI) therapy. Therefore, an algorithm was developed to better assess risk and direct treatment (Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-1416). Here, we provide updated guidance on pharmacologic interventions to prevent/treat aromatase inhibitor-associated bone loss (AIBL).Journal ArticleResearch Support, Non-U.S. Gov'tReviewSCOPUS: re.jinfo:eu-repo/semantics/publishe
Elective surgery for colorectal cancer in the aged : a clinical-economical evaluation
No full textA series of 56 consecutive patients, referred for surgery to a specialized institute, had elective laparotomies with various surgical procedures aimed at curing locoregional colorectal cancer. Data defining patient and tumour-related preoperative, operative and postoperative variables, including costs, were collected. The study group was divided into two age groups ( or = 65 years), which were similar in terms of patient- and tumour-related variables. Differences were not statistically significant (Pounds 440; 95% exact CI; Pounds -50; 1800). There is no evidence to suggest that there are any total charge differences in treating the two age groups, as confirmed by the cost analysis
Étude sur le patois de Valbonnais
No full textA lexical and morphologic description of Valbonnais dialect. A 319-page PhD dissertation under the direction of Prof. Antonin DURAFFOUR (Univ. Stendhal, Grenoble, France, 1943)Description lexicale et morphologique du patois de Valbonnais sous la forme d'un manuscrit de 319 pages.Thèse sous la direction du Prof. Antonin DURAFFOUR (Univ. Stendhal, Grenoble, 1943
- …
